Overview

• A 34-year-old patient in the UAE became the first person to have an external ventricular shunt C. auris infection cleared without intrathecal treatment following a traumatic brain injury.
• Clinicians employed a three-phase antifungal regimen—injectable therapy, IV drips and oral tablets—that eradicated the fungus and enabled discharge after a seven-month hospital stay.
• UK Health Security Agency has classified Candida auris as a notifiable infection, mandating all confirmed cases be reported to strengthen outbreak monitoring and control.
• King’s College London scientists led by Professors Miraz Rahman and Mark Sutton reported preclinical azole derivatives that penetrate fungal cells, disrupt biofilms and protect animal models without toxic effects.
• Candida auris, identified in 2009 and now detected in over 40 countries, persists on surfaces and skin, has a 30–60% fatality rate and its growing resistance is linked to widespread antifungal overuse.